Comparison of Bezafibrate and Simvastatin in the Treatment of Dyslipidaemia in Patients with NIDDM

Effective diabetes care: a need for realistic targets

“…Statins may not be desirable in dyslipidaemia with low concentrations of high density lipoprotein cholesterol and modest hypertriglyceridaemia (>4.5 mmol/l): patients with this pattern were excluded from the secondary prevention statin studies, 4 5 and statins have been found unsatisfactory in such patients 25…”

Current Lipid-lowering Strategies for the Treatment of Diabetic Dyslipidemia: An Integrated Approach to Therapy

“…A comparison of statins relative to fibrates for treatment of dyslipidemia in type 2 diabetes is the subject of several crossover studies (Table 7) [119][120][121][122][123][124][125][126]. The lipid-altering profiles after statin or fibrate therapy were comparable to those described previously in Tables 2 and 3.…”

“…The lipid-altering profiles after statin or fibrate therapy were comparable to those described previously in Tables 2 and 3. Comparative analysis showed that statins were more effective than fibrates at reducing total and LDL-C, whereas fibrates were more effective at reducing triglycerides [119][120][121][122][123][124][125][126]. Both agents were effective at increasing HDL-C.…”

Diabetes: Statins, fibrates, or both?

“…Moreover, in elderly type 2 diabetic patients [13], simvastatin seems to have beneficial effects both on lipid and glucose metabolism and it has been reported [27,28] that statins can improve insulin-mediated glucose uptake, and by consequence, insulin sensitivity. However, other studies have shown either no effect [14][15][16] or varying degrees of elevation in plasma glucose and HbA1c levels after statin treatment [17,18,28]. Using the current knowledge, it seems logical to conclude that statins do not significantly affect glucose control.…”